Active Ingredient History

  • Now
Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis. It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB1 antagonists or inverse agonists on the market or under development for this application, so surinabant is at present mainly being developed as an anti-smoking drug, with possible application in the treatment of other addictive disorders such as alcoholism. Other potential applications such as treatment of ADHD have also been proposed.   Wikipedia

  • SMILES: CCc1c(nn(c2ccc(Cl)cc2Cl)c1c3ccc(Br)cc3)C(=O)NN4CCCCC4
  • Mol. Mass: 522.27
  • ALogP: 6.3
  • ChEMBL Molecule:
More Chemistry
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide | sr147778 | sr 147778 | sr-147778 | surinabant


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue